Allucent Launches Decentralized Clinical Trial Solution
Allucent announced that it has partnered with THREAD to launch Allucent Patient Direct Trials. The new offering brings technology, development, and regulatory expertise to small and emerging biotechnology companies to support them in designing and overseeing customized decentralized clinical trial (DCT) approaches that address their needs.
Allucent Patient Direct Trials leverages this experience to address the needs of many small and emerging biotech companies that may not have the in-house resources required to design and oversee DCTs. Working with THREAD, Allucent's team of regulatory and product development consultants can guide sponsors in determining the most effective and efficient digital strategies for remote engagement and data collection for their studies.
Reference
Allucent Launches Decentralized Clinical Trial Solution at 2023 World Orphan Drug Congress. (2023, May 23). Cision PR Newswire.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
